Featured Blog Posts – May 2013 Archive (6)


Staff
Is the grass greener?

Several weeks ago, I was invited to participate in a discussion focused on how large pharmaceutical companies should communicate with advocacy; how communication needs to be different in rare disease; and more specifically what advocates in rare diseases expect, want, and need from pharmaceutical companies. I was one of…

Continue

Added by Pat Furlong on May 22, 2013 at 12:30pm — No Comments


Staff
Continuing the Quest for Accelerated Approval

Wading through policy is no easy task.  But imagine policy as the white lines on the road, the boundaries within which FDA operates.  Building our case, showing how Duchenne fits into those white lines and demonstrating how and when Accelerated Approval makes perfect sense is the purpose of PPMD’s white paper.   …

Continue

Added by Pat Furlong on May 20, 2013 at 11:51am — No Comments


Staff
UPDATE – Putting Patients First: Recommendations to speed responsible access to new therapies for Duchenne

Two weeks ago, PPMD proudly published Putting Patients First, a white paper outlining recommendations to speed responsible access to new therapies for Duchenne. In that short amount of time, the reaction to this white paper has been phenomenal. From interest by the media to accolades from industry and agencies, we have been truly humbled by the response we have received.

And while the…

Continue

Added by Pat Furlong on May 9, 2013 at 1:00pm — No Comments


Staff
Oh Brother

Guest post by Ivy Scherbarth. Ivy is a Colorado/Wyoming FACES Coordinator for PPMD. Follow Ivy at her blog, Living Duchenne.

 …

Continue

Added by PPMD on May 3, 2013 at 9:50am — 1 Comment


Staff
How YOU Can Speed Up the Clinical Trial Process!

CLINICAL TRIALS – The path to approval.

Typically we think about the Clinical Trial Process in the context of our kids.   We hear about Phase I trials.   Depending on the drug/biologic, many of these compounds will be required to be tested in healthy human subjects.   Some Phase I trials have inclusion criteria, suggesting they are looking for healthy adults of a certain age to take a single or multiple doses of a compound or biologic.   The purpose of the study…

Continue

Added by Pat Furlong on May 1, 2013 at 10:30am — No Comments

Featured Monthly Archives

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2018   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service